hydroxychloroquine for COVID-19: living meta-analysis of clinical studies

Table Graph

hydroxychloroquine - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	1.07 [0.95, 1.21]	< 1	6%	4 studies (4/-)	13.6 %	some concern	not evaluable	moderate	crucial	-
deaths	1.07 [0.97, 1.18]	< 1	0%	25 studies (25/-)	10.0 %	some concern	critical	moderate	crucial	-
deaths (time to event analysis only)	1.08 [0.95, 1.23]	< 1	11%	3 studies (3/-)	12.1 %	some concern	not evaluable	moderate	crucial	-
clinical deterioration	1.17 [0.73, 1.89]	< 1	6%	4 studies (4/-)	25.5 %	some concern	not evaluable	moderate	important	-
clinical improvement	1.02 [0.73, 1.42]	> 1	0%	1 study (1/-)	54.6 %	NA	not evaluable		important	-
clinical improvement (14-day)	0.95 [0.71, 1.25]	> 1	0%	3 studies (3/-)	35.1 %	low	not evaluable	high	important	-
clinical improvement (28-day)	0.97 [0.69, 1.37]	> 1	0%	1 study (1/-)	43.2 %	NA	not evaluable		important	-
clinical improvement (7-day)	1.16 [0.84, 1.61]	> 1	0%	1 study (1/-)	81.4 %	NA	not evaluable		important	-
clinical improvement (time to event analysis only)	0.94 [0.78, 1.14]	> 1	0%	3 studies (3/-)	28.0 %	some concern	not evaluable	moderate	important	-
death or ventilation	1.13 [1.03, 1.24]	< 1	0%	5 studies (5/-)	0.5 %	some concern	not evaluable	moderate	important	-
hospital discharge	0.95 [0.76, 1.20]	> 1	0%	3 studies (3/-)	33.6 %	some concern	not evaluable	moderate	important	-
radiologic improvement (7-day)	3.43 [1.10, 10.70]	> 1	0%	1 study (1/-)	98.3 %	NA	not evaluable		important	-
viral clearance	0.46 [0.04, 5.75]	> 1	0%	1 study (1/-)	27.7 %	NA	not evaluable		important	-
viral clearance by day 14	1.42 [0.26, 7.76]	> 1	0%	1 study (1/-)	65.5 %	NA	not evaluable		important	-
ICU admission	1.19 [0.72, 1.96]	< 1	4%	2 studies (2/-)	24.6 %	some concern	not evaluable	moderate	non important	-
off oxygenation	0.98 [0.64, 1.51]	> 1	0%	1 study (1/-)	46.4 %	NA	not evaluable		non important	-
safety endpoints 00
cardiac arrest	1.92 [0.35, 10.49]	< 1	0%	1 study (1/-)	22.7 %	NA	not evaluable		important	-
serious adverse events	1.26 [0.56, 2.84]	< 1	0%	1 study (1/-)	28.7 %	NA	not evaluable		important	-
adverse events	1.38 [1.08, 1.76]	< 1	0%	7 studies (7/-)	0.5 %	some concern	not evaluable	moderate	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

hydroxychloroquine - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00